PMS38 ESTIMATING WORK PRODUCTIVITY: EFFECTS OFTRAMADOL EXTENDED-RELEASE TREATMENT  by Benson, C et al.
sleep questionnaire or on the derived MOS sleep scales. Signiﬁ-
cant improvement in the abatacept group compared to control
on sleep adequacy, sleep disturbance, somnolence and both sleep
problem indices I and II were found. For both studies,
sleep quantity was not signiﬁcantly difference between treatment
groups, but optimal sleep signiﬁcantly improved in the abatacept
vs control group: ATTAIN (18% vs -12%, p < 0.0001) and AIM
(16% vs 5%, p = 0.0214). CONCLUSION: Treatment with
abatacept improves several different aspects of sleep in RA
patients. In particular, sleep disturbance and sleep problems
given by index II are reduced, and optimal sleep is improved.
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OBJECTIVE: To examine the validity, reliability, and sensitivity
to change of a simple measure of activity participation for rheu-
matoid arthritis (RA) clinical trials. Joint damage from RA sig-
niﬁcantly limit patients’ participation of daily work and
non-work activities, however, few instruments were available to
measure treatment effect on this aspect. METHODS: We mea-
sured activity participation in two randomized clinical trials of
abatacept in active RA patients. Activity participation was
assessed by two items: 1) the number of days in the past month
a patient was unable to perform usual activities (paid or unpaid
work, or any other daily activities), and 2) how often a patient
was able to perform activities completely (scored 1–6, ranging
from none to all of the time). For construct validity, corre-
lations between the two activity items with clinical response
and patient-reported outcomes were examined. Intraclass corre-
lation coefﬁcient (ICC) was used to assess test-retest reliability,
and standardized effect sizes (SES) were calculated to evaluate
sensitivity to change. RESULTS: In both studies at baseline,
patients were limited for 15 days per month in usual activities
and the score on activity completion was 3.7. After treatment,
patients with EULAR clinical responses of good, moderate,
none, gained back 11, 9, and 4 days of activity respectively, and
patients who achieved minimal disease activity state gained
12 days vs. those who did not (7 days). Similar pattern was
observed for the activity completion score. Moderate to strong
correlations (0.5–0.6) between the two activity items with
physical function, patient global, pain, and fatigue were found.
The ICC for reliability was 0.6, and the SES was 0.5, indicating
good response to change. CONCLUSION: The simple activity
participation measure reﬂects true changes in patient clinical
status and quality of life. It is valid, reliable, and sensitive to
change, which suggests it is a suitable outcomes measure for
clinical trials.
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OBJECTIVE: To estimate work productivity for patients treated
with tramadol extended–release (ER) or placebo. METHODS:
Intent-to-treat patients (18–65 years old) with chronic osteoar-
thritis pain from a 12-week, randomized, double-blind, placebo-
controlled, ﬁxed-dose study and treated with tramadol ER
(100–400 mg) or placebo were compared. Work productivity
was not assessed within the study, it was estimated using an
imputation methodology. This imputation method cross-walks
other health measures into Work Limitations Questionnaire
(WLQ) scores. The WLQ is a validated questionnaire assessing
health-related decrements in job performance and work produc-
tivity (“presenteeism”). According to this method, mean change
in the Western Ontario and McMaster Universities (WOMAC)
Osteoarthritis total index scores were multiplied by the regres-
sion coefﬁcients established for the WLQ and WOMAC. Produc-
tivity gains were translated to annual US dollars inﬂated to 2007.
RESULTS: Baseline characteristics of tramadol ER and placebo
groups were comparable. After 12 weeks of treatment, the tra-
madol ER treated patients signiﬁcantly improved than placebo
(WOMAC score of 23 vs. 16 points, p = 0.002). This 23 points
improvement in WOMAC when imputed to WLQ translated
into improvement of WLQ time management (8.15%), physical
demands (11.78%), mental-interpersonal (5.99%), overall
output demands (6.95%) and improvement in work productivity
(1.96%). The improvement observed in the tramadol ER patients
when aggregated to annual dollars per employee in 2007 ranged
from [$1201–$7218], was numerically higher than placebo
treated patients [$882–$5098]. Sensitivity analyses using other
health-measures resulted in similar ﬁndings. CONCLUSION:
Treatment with tramadol ER resulted in signiﬁcant improvement
in pain and physical function, when imputed to WLQ corre-
sponded to productivity improvement.
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OBJECTIVE: To estimate loss of employable life-years over time
in patients with rheumatoid arthritis (RA). METHODS: We used
a Markov model to estimate employable life-years using data
from ASPIRE, a randomized clinical trial comparing the efﬁcacy
and safety of inﬂiximab + methotrexate (MTX) (IFX group)
and placebo + MTX (MTX group) among early RA patients.
Employability state was deﬁned as ‘unemployable’ if patients
were unemployed and felt unable to work even if a job was
available or ‘employable’ if patients were employed or felt well
enough to work if a job were available. The one-year transition
probability of employability was estimated using a logistic
regression model, and loss of employable life-years was estimated
using a two-state Markov model. RESULTS: For a patient at age
45 years, 31.4 % of female and 29.7% of male were unemploy-
able using the regression model. For patients starting at age 45
and employable, the probability of remaining employable after
one-year of treatment was 0.928 in males and 0.905 in females in
the IFX group, and 0.899 in males and 0.867 in females in the
MTX groups, respectively. For patients unemployable, the prob-
ability to be employable after one-year treatment was 0.481 in
males and 0.405 in females in the IFX groups, and 0.390 in males
and 0.319 in females in the MTX groups, respectively. In the
Markov model, after 10 years at age 55, 18.5% of females and
14.1% of males in the IFX groups, and 30.7% of females and
24.2% of males in the MTX groups will be unemployable. On
average, 0.99 employable life-years will be saved per patient over
10 years in IFX-treated patients compared to MTX-treated
patients. CONCLUSION: This analysis presents a new method
to estimate employable life-years using a Markov model, and
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